Auayporn Nademanee

Summary

Affiliation: City of Hope National Medical Center
Country: USA

Publications

  1. doi request reprint Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of
    Auayporn P Nademanee
    City of Hope National Medical Center, Duarte, CA 91010, USA
    Biol Blood Marrow Transplant 18:1564-72. 2012
  2. pmc High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors
    Auayporn Nademanee
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Biol Blood Marrow Transplant 17:1481-9. 2011
  3. doi request reprint Transplantation for non-Hodgkin lymphoma
    Auayporn Nademanee
    Division of Hematology and Hematopoietic Cell Transplantation, 1500 E Duarte Road, Duarte, CA 91010, USA
    Expert Rev Hematol 2:425-42. 2009
  4. ncbi request reprint Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma
    A Nademanee
    Division of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Clin Lymphoma 1:46-54. 2000
  5. ncbi request reprint Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma
    Henry C Fung
    City of Hope Comprehensive Cancer Center, Hematology, Durante, California 91010, USA
    Biol Blood Marrow Transplant 13:594-600. 2007
  6. ncbi request reprint Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B
    Auayporn Nademanee
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Semin Hematol 43:240-50. 2006
  7. pmc A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Auayporn Nademanee
    Division of Hematology and Hemapoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Blood 106:2896-902. 2005
  8. ncbi request reprint Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Amrita Krishnan
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    J Clin Oncol 26:90-5. 2008
  9. ncbi request reprint Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma
    Roberto Rodriguez
    Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91001, USA
    Biol Blood Marrow Transplant 12:1326-34. 2006
  10. doi request reprint Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
    Robert Chen
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Ann Hematol 90:803-8. 2011

Detail Information

Publications25

  1. doi request reprint Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of
    Auayporn P Nademanee
    City of Hope National Medical Center, Duarte, CA 91010, USA
    Biol Blood Marrow Transplant 18:1564-72. 2012
    ..Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population...
  2. pmc High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors
    Auayporn Nademanee
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Biol Blood Marrow Transplant 17:1481-9. 2011
    ..More effective and novel therapies are needed for patients with high-risk disease (PIT 3-4 factors) and allogeneic HCT should be explored in these patients...
  3. doi request reprint Transplantation for non-Hodgkin lymphoma
    Auayporn Nademanee
    Division of Hematology and Hematopoietic Cell Transplantation, 1500 E Duarte Road, Duarte, CA 91010, USA
    Expert Rev Hematol 2:425-42. 2009
    ..The outcomes of auto-HCT and allo-HCT for various lymphomas are reviewed...
  4. ncbi request reprint Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma
    A Nademanee
    Division of Hematology and Bone Marrow Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Clin Lymphoma 1:46-54. 2000
    ..The development of a second malignancy is a serious complication of high-dose therapy, which requires close surveillance...
  5. ncbi request reprint Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma
    Henry C Fung
    City of Hope Comprehensive Cancer Center, Hematology, Durante, California 91010, USA
    Biol Blood Marrow Transplant 13:594-600. 2007
    ..Our mature results from this study suggest that in patients with primary progressive or poor risk recurrent HL, this tandem ASCT program is effective and well tolerated and compares favorably with the conventional single transplant...
  6. ncbi request reprint Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B
    Auayporn Nademanee
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Semin Hematol 43:240-50. 2006
    ..Innovative approaches are needed for primary refractory and chemoresistant relapsed DLCL-B since these patients have very poor outcomes after ASCT...
  7. pmc A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Auayporn Nademanee
    Division of Hematology and Hemapoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010, USA
    Blood 106:2896-902. 2005
    ..We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without an increase in transplant-related toxicity or delayed engraftment...
  8. ncbi request reprint Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Amrita Krishnan
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    J Clin Oncol 26:90-5. 2008
    ....
  9. ncbi request reprint Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma
    Roberto Rodriguez
    Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91001, USA
    Biol Blood Marrow Transplant 12:1326-34. 2006
    ....
  10. doi request reprint Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
    Robert Chen
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    Ann Hematol 90:803-8. 2011
    ..1% (95% CI 5.1, 31.4) at 2 years. The incidence of grade II-IV aGVHD was 45.8% and 8.3% for grade III-IV. Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions...
  11. pmc Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
    Smita Bhatia
    Population Sciences, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Blood 110:3784-92. 2007
    ..This study demonstrates that mortality rates remain twice as high as that of the general population among 15-year survivors of HCT, and that the survivors face challenges affecting their health and well-being...
  12. doi request reprint A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation
    Mark H Kirschbaum
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 18:432-40. 2012
    ..With a median follow-up of 17 months, only 2 patients relapsed, and 4 patients died. Clofarabine plus melphalan at dose level 2 is a well-tolerated conditioning regimen with activity in patients with advanced acute myelogenous leukemia...
  13. ncbi request reprint Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation
    Shirong Wang
    Department of Transfusion Medicine, Division of Pathology, City of Hope National Medical Center, Duarte, California 91010, USA
    Transfusion 47:2207-16. 2007
    ..The aim of this retrospective study was to determine whether the effectiveness of mobilization and collection is an independent prognostic factor for autologous stem cell transplantation outcome...
  14. pmc Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
    Robert Chen
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA
    Blood 119:6379-81. 2012
    ..8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT...
  15. ncbi request reprint Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma
    Ravi Bhatia
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA
    J Clin Oncol 23:6699-711. 2005
    ..The phenomenon of hematopoietic reconstitution after autologous HCT and the role of proliferative stress in the pathogenesis of t-MDS/AML are poorly understood...
  16. pmc Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma
    Amrita Krishnan
    Department of Hematology Hematopoietic Cell Transplantation, City of Hope, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 18:441-50. 2012
    ..8% for TBI at 4 years (P < .01). Our data demonstrate that RIT-based conditioning had a similar relapse incidence to TBI, with lower toxicity, resulting in improved overall survival, particularly in patients with ≥2 prior regimens...
  17. ncbi request reprint Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients
    Joel Y Sun
    Division of Hematology and HCT, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 13:197-205. 2007
    ..01). Our observations indicate that, in T-replete unrelated HCT, iKIRL mismatches and the absence of iKIRLs confer higher risk to patients after HCT...
  18. ncbi request reprint Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?
    Amrita Krishnan
    Division of Hematology Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 12:641-7. 2006
    ..Furthermore, the similar plateau in the survival curve for the DLCL and FLCL patients suggests that the behavior of FLCL is similar to that of DLCL and that FLCL is potentially curable with ASCT...
  19. ncbi request reprint Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides
    Arturo Molina
    City of Hope Comprehensive Cancer Center, Division of Hematology and Hematopoietic Cell Transplantation, 1500 E Duarte Rd, Duarte, CA 94305, USA
    J Clin Oncol 23:6163-71. 2005
    ..We conducted a retrospective study to evaluate the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) in this patient population...
  20. pmc Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    Mark Kirschbaum
    City of Hope, Duarte, CA, USA
    J Clin Oncol 29:1198-203. 2011
    ..We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma...
  21. pmc Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
    Smita Bhatia
    City of Hope Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010 3000, USA
    Blood 105:4215-22. 2005
    ..4) when compared with siblings. Although mortality rates approach that of the general population after 10 years in certain subgroups, long-term survivors of autologous HCT continue to face challenges affecting their health and well-being...
  22. ncbi request reprint Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease
    Francisco Lopez
    Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California 91010, USA
    Biol Blood Marrow Transplant 11:307-13. 2005
    ..These data suggest that MMF is an active, well-tolerated agent in the treatment of cGVHD and may have a beneficial effect on the survival of patients with this complication...
  23. ncbi request reprint Thymoma-associated severe aplastic anemia treated with surgical resection followed by allogeneic stem-cell transplantation
    Vijay Trisal
    Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA, USA
    J Clin Oncol 25:3374-5. 2007
  24. ncbi request reprint Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan
    Arturo Molina
    Biogen Idec Inc, San Diego, CA 92122, USA
    Curr Stem Cell Res Ther 2:239-48. 2007
    ..Studies of (90)Y ibritumomab tiuxetan in the setting of allogeneic stem cell transplantation appear promising as well...
  25. ncbi request reprint Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced
    Robert Chow
    StemCyte International Cord Blood Center, Arcadia, California 91722, USA
    Biol Blood Marrow Transplant 13:1346-57. 2007
    ..These results demonstrate that PD CBT is safe and effective, and that eliminating RBC reduction or depletion improves cell recovery during CB processing, resulting in a larger proportion of the inventory with high NC number...